Deprescribing conversations: a closer look at prescriber–patient communication. (December 2018)

• Record Type: Journal Article
• Authors: Turner, Justin P.; Richard, Claude; Lussier, Marie-Thérèse; Lavoie, Marie-Eve; Farrell, Barbara; Roberge, Denis; Tannenbaum, Cara
• Is Part Of: Therapeutic advances in drug safety. Volume 9:Number 12(2018)
• Page Start: 687
• Page End: 698
• Publication Date: 2018-12
• Subjects: aged -- decision-making -- deprescribing -- education -- potentially inappropriate medication -- primary health care -- public health professional -- shared; Pharmacoepidemiology -- Periodicals; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Pharmaceutical Preparations -- adverse effects -- Periodicals; Toxicology -- Periodicals; 615.70405
• DOI: 10.1177/2042098618804490
• Languages: English
• ISSNs: 2042-0986

Abstract

Background: Little is known about the initiation, style and content of patient and healthcare provider communication around deprescribing. We report the findings from a content analysis of audio-recorded discussions of proton pump inhibitor (PPI) and benzodiazepine deprescribing in primary care. Methods: Participants were healthcare providers ( n = 13) from primary care practices ( n = 3) and patients aged ⩾65 ( n = 24) who were chronic users of PPIs or benzodiazepines. The EMPOWER educational brochures were distributed prior to ( n = 15) or after ( n = 9) the patient's usual healthcare provider appointment. Conversations were audio-recorded and coded using MEDICODE to analyze who initiated different themes, whether they followed a monologue or dialogue style, and to what extent the thematic content addressed issues pertaining to: 'dosage/instructions, ' 'medication action and efficacy, ' 'risk/adverse effects, ' 'attitudes/emotions, ' 'adherence' and 'follow up.' Descriptive analysis of the conversations was performed with comparison between patients who received the EMPOWER brochure before or after their appointments. Results: Patients were mostly women (67%) with a mean age of 74 ± 6 years. For PPI users, prior education resulted in a greater proportion of themes initiated by patients (44% versus 17%) and maintaining dialogue-style conversations (48% versus 28%). Among benzodiazepine users, conversation initiation (52% versus 47%) and conversation style was similar between both groups. The content of deprescribing conversations for PPIs revealed that patients and their healthcare providers focused less on 'dosage/instructions, ' and more on the 'medication action and efficacy' and the necessity for 'follow up.' Conversations about stopping benzodiazepines were more likely to stagnate on the 'if' rather than the 'how.' Conclusion: The initiation, style and content of the conversations varied between PPI and benzodiazepine users, suggesting that healthcare providers will need to tailor deprescribing conversations accordingly.